Proinflammatory effects have also been reported in colorectal cancer patients treated with RT inhibitors and in similarly treated colorectal cancer cell lines, particularly those with p53 mutations (168), which are hypothesized to arise from residual ORF2p activity and lead to DNA damage or accumulation of DNA replication intermediates. This evidence concerns the gene TP53 and colorectal cancer.